Background: Cathepsin S is a member of the family of cysteine lysosomal proteases preferentially expressed in macrophages and microglia and is active after prolonged incubation in neutral pH. Upon activation of macrophages by a number of inflammatory mediators, there is an increase in secreted cathepsin S activity accompanied by a decrease in cellular cathepsin S activity and protein content, as well as a decrease in cathepsin S mRNA. The decrease in cathepsin S mRNA and protein at the cellular level is in contrast to the response observed in some in vivo scenarios. Materials and Methods: We investigated the effect of basic fibroblast growth factor (bFGF) and nerve growth factor (NGF), two growth factors present during cell injury and inflammation but not known to activate macrophages and microglia, on the expression of cathepsin S, cathepsin B, and cathepsin L mRNAs in these cells, and on cathepsin S activity. We then tested the ability of cathepsin S to degrade myelin basic protein, and amyloid ,B peptide at both acidic and neutral pH.
Introduction
The role of "activated" macrophages and microglia during inflammatory reactions in the central and peripheral nervous system has been well established (1, 2) . Typical activation signals in-clude bacterial endotoxins or inflammatory cytokines, e.g., interferons, interleukins, colonystimulating factors, and tumor necrosis factor. Following activation, macrophages can secrete a wide variety of biologically active products, including proteases, that are important mediators of the tissue destruction and fibrosis characteristic of chronic inflammation (3, 4) . We have previously shown that the cysteine lysosomal protease, cathepsin S, is secreted from macrophages and microglia by the above activation signals (5, 6) . Cathepsin S retains activity after prolonged incubation at neutral pH, whereas all the other cysteine lysosomal proteases, e.g., cathepsins B, H, L, and 0, become irreversibly inactivated (7, 8) . Thus, cathepsin S is a good candidate for tissue destruction and remodeling of the extracellular matrix (ECM) in both acidic and nonacidic extracellular environments (9) .
We and others have demonstrated that cathepsin S expression is restricted to cells of the mononuclear-phagocytic system (5, 10) . In the central nervous system (CNS), microglia are responsive in many pathological scenarios of neuronal degeneration whereby an inflammatory process may or may not be evident, e.g., in Alzheimer's disease, multiple sclerosis, AIDS, Parkinson's disease, amyotrophic lateral sclerosis, and stroke (2, 11, 12) . In the peripheral nervous system (PNS) and the CNS, macrophages and microglia play a key role during Wallerian degeneration (1 1). Cathepsin S is able to degrade a number of components of ECM including those found in the CNS, such as neurocan, phosphacan, and basement membrane heparan sulfate proteoglycan (5, 6, (13) (14) (15) . Thus, secreted cathepsin S from mononuclear-phagocytic cells may play a role during a multitude of inflammatory and degenerative processes in the periphery and in the brain (2, 11, 12) .
We have shown that secretion of cathepsin S from macrophages and microglia is positively regulated by activating inflammatory stimuli; however, these agents cause a decrease in its mRNA, protein, and cellular protease activity (6) . Also, following entorhinal cortex lesion of rat brain, a classical in vivo paradigm for anterograde neuronal degeneration and microglial activation, there is increased mRNA for cathepsins S, B, and L in the outer molecular layer of the ipsilateral hippocampus, with an overwhelming response by cathepsin S, that is localized to microglia (5). In addition, others have shown that cathepsin L can be up-regulated in murine thioglycolate-elicited peritoneal macrophages; in this in vivo scenario the agents directly responsible are also unknown (16) . Therefore, it is intuitive that factors other than those mentioned above, must exist to up-regulate cathepsin levels inside cells, and that they may be associated with macrophage activation. Here we examine the potential regulation of cathepsin S expression and activity in macrophages and in microglia by two prototypic neurotrophic factors that are known to have different signal transduction properties than pro-inflammatory agents. We demonstrate that cathepsin S, cathepsin B, and cathepsin L mRNA expression is positively regulated by both bFGF and nerve growth factor (NGF). We also show that cathepsin S has the ability to degrade myelin basic protein (MBP), and amyloid ,B peptide in vitro, and propose a role for cathepsin S in neurodegenerative processes. RNA Isolation and Northern Blot Analysis Total RNA was isolated using the acid guanidinium thiocyanate (GTC) -phenol-chloroform extraction method (17) and was fractionated in agarose gels and transferred onto Gene Screen Plus membranes (DuPont NEN, Boston, MA) as described previously (6) . Membranes were hybridized to [32P]-radiolabeled cDNA probes as described previously (6, 18) . The membranes were exposed to a phosphor screen and quantitative analysis of mRNA bands was performed on a phosphorimager (Molecular Dynamics, Sunnyvale, CA); results were standardized to probed 18S rRNAs.
Materials and Methods

Cell
Cathepsin S Activity Determination Enzymatic assays of conditioned media (C.M.) and cellular lysates were performed as previously described (5, 6) . Cell lysates were subjected to a 1-hr neutral pH incubation step prior to cathepsin S activity determination as previously described(6); this step has been shown to inactivate the other lysosomal proteases with substrate specificity similar to that of cathepsin S (8, 15 We examined the effect of bFGF and NGF on the mRNA transcripts of cathepsins S, B, and L in N1 3 microglial and RAW 264.7 macrophage cell lines. Both bFGF and NGF dose-dependently increased the levels of all three mRNAs. This effect is opposite that by LPS, IFN-,y, TNF-a, IL-i a, IFN-a, and GM-CSF, which are known to promote activation of microglia and macrophages (6) . Treatment of RAW macrophages for 24 hr with bFGF increased the levels of cathepsin S, B, and L mRNAs about 1.5-fold (p S 0.05; Fig. IA , B). Basic FGF had a more potent and dose-dependent stimulatory effect on cathepsin mRNA expression in microglial cells compared to macrophages (Fig. IC, D) . Treatment of N13 microglial cells with bFGF increased cathepsin S, B, and L mRNA levels about 3.2-to 4.0-fold (p -0.05). Furthermore, the treatment of microglia with bFGF produced a biphasic effect with maximal increases in cathepsin mRNAs at 1 ng/ml bFGF.
We examined the effects of NGF on cathepsin mRNA levels in macrophages and microglia. NGF treatment led to an increase in all three transcripts in both macrophages and microglia and was more effective than bFGF (Fig. 2) . Again, the effect was biphasic with an intermediate dose, being more stimulatory than higher doses of NGF (Fig. 2B, D SEM from three independent experiments. Graphs represent densitometry of specific bands performed on phosphorimager.
crease in cell numbers after 24 or 48 hr compared to controls treated with MSFM alone (Fig. 3A, B) . In agreement with this finding is the observation that bFGF is not a direct mitogen for isolated microglia (19) . In addition, treatment of N13 cells with 1 ng/ml bFGF and 100 ng/ml heparin had no effect on cell proliferation (data not shown). Treatment of N13 microglial cells with NGF under the same conditions that elevated cathepsin mRNA levels demonstrated no effect on cell number after 24 hr, but displayed a small (23%) increase in microglial cell number after 48 hr of treatment compared to treatment with MSFM alone (Fig. 3B) . RAW (Fig. 3A) . Therefore, the dramatic increase in cathepsin mRNA levels after 24-hr treatment of Ni 3 microglia and RAW macrophages with bFGF and NGF could not be accounted for by enhanced proliferation of these cells. We next analyzed whether bFGF could stimulate the secretion of cathepsin S activity from microglia and macrophages. After treatment of cells for 24 hr with 0.1, 1, and 10 ng/ml of bFGF, both the cellular and the secreted cathepsin S activity by microglia and macrophages were elevated. In correlation with the observed increase in mRNA levels for cathepsin S, we found that a low dose of bFGF (0.1 ng/ml) increased the cellular activity to 170% and 160% (p < 0.05) compared to controls in N 13 and RAW cells, respectively (Fig. 4A, B (Fig. 4C, D) . Thus, 24-hr treatment of microglia and macrophages with bFGF and NGF resulted in an increase in cathepsin S, B, and L mRNAs, and increased cellular and secreted cathepsin S activity. Regulation of cathepsin S by neurotrophic growth factors is overall different from its regulation by LPS and proinflammatory cytokines.
To further characterize bFGF-induced protease activity, we analyzed time courses of cathepsin S secretion from N13 and RAW macrophages. First, N1 3 cells were treated with various doses of bFGF for 12 hr or 24 hr and the C.M. and cell lysates were assayed for cathepsin S activity. We observed that after 12 hr N13 microglia contained elevated secreted cathepsin S activity in their C.M. with a peak of 1.6-fold at 1 ng/ml bFGF treatment and decreased cellular activity (data not shown). This decrease could be due to the increased secretion of cathepsin S from intracellular stores. However, after 24 hr of treatment, bFGF caused a significant increase in cellular cathepsin S activity to 171 % and 152 % compared to controls. The level of cathepsin S activity in C.M. from N1 3 cells treated for 24 hr was 2-to 3-fold higher than after 12 hr of treatment, suggesting continual secretion (data not shown). The increase in cellular cathepsin S activity induced by bFGF after 24 hr correlates well with the increased mRNA levels in these cells (Fig. IB) .
We also followed the time course of cathepsin S activity in RAW macrophages after bFGF treatment. As in N13 cells above, cellular and secreted cathepsin S activity increased after 24 hr of treatment (Fig. 5 ). There is a further elevation of enzyme activity after 48 hr of treatment compared to that found at 24 hr (Fig. 5A ). This may be due to increased synthesis of cathepsin S protein since its mRNA is increased after 24 hr (Fig. 1A) . After 48 hr of bFGF treatment, cathepsin S activity is relatively decreased inside cells compared to control cells (Fig. 5A) 7.5 (Fig. 6) . A similar selective decrease of the basic protein band was also seen upon digestion at pH 6.5 (data not shown). This finding suggests a possible role for cathepsin S in the breakdown of myelin during various demyelinating neuropathies. Activated microglia surround both diffuse and mature senile plaques in the brains of patients with Alzheimer's disease (21) (22) (23) (Fig. 7) , or by silver staining (data not shown). Cathepsin S was able to degrade most of the monomeric A,B peptide and substantial amounts of the dimeric peptide within 1 hr at acidic pH (Fig. 7, lane 2) . At neutral pH both the monomeric and dimeric peptides were substantially degraded to the same extent (Fig. 7, lane  3) . These data suggest that cathepsin S may take part in the clearence of Af3 peptides in vivo, either intracellularly or extracellularly.
Discussion
In this study we have determined that the neurotrophic factors bFGF and NGF can positively regulate the expression of cysteine lysosomal proteases cathepsins B, L, and S in macrophages and microglia, as well as increase secretion of cathepsin S. Murine fibroblasts stimulated with phorbol ester, platelet-derived growth factor (PDGF), NGF, and FGF can increase their secretion of an inactive cathepsin L precursor (major excreted protein), suggesting possible regulation of cathepsins by growth factors (25) (26) (27) (32) . Following entorhinal cortex lesions, increased bFGF immunoreactivity was found in the astrocytes and surrounding ECM (28) , which would support a paracrine mechanism for increased cathepsin mRNA expression in microglia. Macrophages also produce bFGF, which in the brain can potently stimulate the proliferation of perineuronal satellite cells, endothelial cells, vascular pericytes, macrophages, and glial cells (33) . Microglia contain specific receptors for bFGF on their cell surface (34, 35) , and in a model of autoimmune inflammation of the CNS it was found that bFGF and FGFR-1 are induced in activated microglia and brain macrophages (36) . Furthermore, the phagocytic properties of microglia are not affected by bFGF (20) .
In the CNS, NGF is synthesized and released from both astrocytes and LPS-stimulated microglia (37) (38) (39) . Extracellular NGF can be chemotactic for, as well as taken up by, microglia (37, 38, 40) . Thus, microglia must have specific receptors for NGF, which may promote gene expression, proliferation, or both. Following a peripheral nerve lesion, the recruitment of macrophages is important for Wallerian degeneration and for NGF synthesis by non-neuronal cells, which is essential for sensory axon maintenance and regrowth (41) . Macrophages themselves can synthesize NGF upon stimulation with LPS (38, 42) , but also produce IL-I upon their activation, which increases the expression of NGF in the Schwann and fibroblast-like cells associated with peripheral nerves (43) . During CNS or peripheral nerve injury, inflammation in the brain, or neurodegenerative diseases, bFGF and NGF are released and have the potential to act upon microglia and macrophages that are migrating and actively responding in these scenarios.
Our data are the first evidence that bFGF regulates mRNA expression of cysteine lysosomal proteases. Along this line, we hypothesize that growth factors like bFGF and NGF released during injury from neurons and astrocytes in vivo interact with microglia and macrophages, and lead to an increase of cathepsin S, B, and L mRNA expression. Basic FGF also increases cathepsin S protease activity in these cells and increases the secretion of active enzyme. Activation of these cells by inflammatory mediators in turn decreases cathepsin S, B, and L mRNAs, while increasing secretion of cysteine lysosomal protease activity (6) . Therefore, there must be a fine balance between regulation by growth factors and by pro-inflammatory agents during neuronal degeneration. The order in which these two types of signaling molecules act on macrophages and microglia is currently unknown, but alteration in their equilibrium may contribute to pathological states.
One of the major functions of microglia and macrophages is phagocytic removal of dead cells or cell remnants during brain development and after injury in adult brain (44) . The ability of cathepsin S to degrade MBP at acidic and neutral pH and its potential to be secreted together raise the possibility of involvement of cathepsin S in demyelinating diseases. Microglia and macrophages play a pivotal role in establishing these neuropathies, functioning both as antigen-presenting cells as well as effector cells that actively strip off myelin sheets (2, 21, 45) . Although the mechanism by which the myelin sheath is degraded in these diseases is not known, increased activity of both acid and neutral proteases has been demonstrated in tissues from experimental allergic encephalomyelitis animals and multiple sclerosis patients in correlation with the disappearance of myelin proteins (21) . During Wallerian degeneration, a model for secondary demyelination in the PNS, rapid loss of myelin-specific proteins is accompanied with an increase in many lysosomal enzymes (11, 46) . In addition, NGF levels have been found to be elevated in the serum of patients and correlated to the degree of inflammation associated with autoimmune disorders, such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus (42) . Our findings that cathepsin S degrades MBP in vitro, an important component of the myelin sheath, and that cathepsin S mRNA expression and secretion are regulated by bFGF and NGF and by inflammatory agents, suggest a role for cathepsin S during inflammatory processes associated with neuronal degeneration (6) . Further in vivo studies are required to confirm this hypothesis.
Activated microglia surrounding senile amyloid plaques and a low-level inflammatory response are characteristic for Alzheimer's disease (22, 23) . Immunoreactive cathepsin S is increased in Alzheimer's and Down syndrome brains, and is localized in the vicinity of activated microglia and degenerating neurons (22 In summary, we have shown that growth factors regulate the expression of cysteine lysosomal proteases in macrophages and microglia. More specifically, in response to bFGF and NGF, cathepsin S mRNA and enzyme activity are increased. This fact, and the ability of cathepsin S to degrade MBP and Af3 both at acidic and neutral pH, suggest that disregulation of these factors may accompany pathological changes during inflammatory and degenerative processes in the periphery and in the brain.
